<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3266">
  <stage>Registered</stage>
  <submitdate>18/08/2011</submitdate>
  <approvaldate>18/08/2011</approvaldate>
  <nctid>NCT01421069</nctid>
  <trial_identification>
    <studytitle>Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis</studytitle>
    <scientifictitle>An Open-label Extension Study To Assess The Long-term Safety And Clinical Benefit Of Etanercept In Children And Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-related Arthritis, Or Psoriatic Arthritis Who Were Previously Enrolled In Protocol 0881a1-3338-ww(b1801014)</scientifictitle>
    <utrn />
    <trialacronym>CLIPPER2</trialacronym>
    <secondaryid>0881A1-3342</secondaryid>
    <secondaryid>B1801023</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Juvenile Idiopahtic Arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - etanercept

Experimental: 1 - 


Treatment: drugs: etanercept
Subjects aged &lt;18 years and less than or equal to 62 kg will receive etanercept SC at a dose of 0.8 mg/kg QW (up to a maximum dose of 50 mg QW).
Subjects aged greater than or equal to 18 years or &gt;62 kg will receive etanercept SC at a dose of 50 mg QW.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Occurrence of malignancy</outcome>
      <timepoint>up to 8 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Occurrence of withdrawals from investigational product</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physician's Global Assessment of Disease Activity on a 21-circle visual analogue scale</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient/Parent Global Assessment on a 21-circle VAS</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>C-reative protein</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Childhood Health Assessment Questionnaire (CHAQ) for subjects less than 18 years of age; Health Assessment Questionnaire (HAQ) for subjects greater than or equal to 18 years of age.</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ACR Pediatric 30, 50, 70, 90, and 100</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Individual components of the ACR Pediatric Assessments</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain Assessment on a 21-circle VAS</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of morning stiffness in minutes</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically inactive disease defined as follows per Wallace Criteria</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Juvenile Arthritis Disease Activity Score (JADAS)</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Back Pain and Nocturnal Back Pain on a 100 mm VAS (ERA subjects only)</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bath Ankylosing Spondylitis Metrology Index</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body Surface Area (PsA subjects only)</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physician Global Assessment of Psoriasis (PsA subjects only)</outcome>
      <timepoint>up to 8 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Receipt of at least 1 dose of investigational product (etanercept) and participation for
        approximately 96 weeks in study 0881A1-3338 (B1801014)

        Personally signed and dated informed consent document (and assent document, as applicable)
        indicating the subject (or legally representative/guardian) has been informed of all
        pertinent aspects of the study.</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>30</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria for subject planning to continue investigational product:

        withdrawal from investigational product in study 0881A1-3338 for any reason (safety or
        non-safety).

        History of maliginancy other than squamous cell, basal cell carcinoma or cervical carcinoma
        in situ.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>109</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/03/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>The Children's Hospital at Westmead - Westmead, Sydney</hospital>
    <hospital>Royal Children's Hospital - Parkville, Melbourne</hospital>
    <postcode>2145 - Westmead, Sydney</postcode>
    <postcode>3052 - Parkville, Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Santander</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bremen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>St. Augustin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Chieti SCALO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Vilnius</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>D.f.</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Nis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Piestany</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Ljubljana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a 8-year extension study in pediatric subjects who have been diagnosed with one of 3
      subtypes of Juvenile Idiopathic Arthritis (JIA) [extended oligoarticular JIA, enthestitis
      related arthritis (ERA), or psoriatic arthritis (PsA)] who have completed approximately 96
      weeks of participation in study 0881A1-3338 (B1801014). The study contains an active
      treatment period, withdrawal/re-treatment period and a observational period (non-treatment).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01421069</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>